SurvodutideDual GLP-1/glucagon receptor agonist
Survodutide combines GLP-1 and glucagon receptor activity. Its liver-disease programme is useful to examine because improvement in inflammation and improvement in scarring are not the same outcome.
What is Survodutide?
Survodutide is a dual GLP-1 and glucagon receptor agonist investigated in obesity and MASH.
How it works
It combines appetite-related effects with metabolic signalling. Its liver research concerns more than simply lowering fat on an imaging scan.
Effects studied
What does the evidence show?
Randomised metabolic and MASH studies; archived references retained
Two related clinical problems
Obesity and metabolic dysfunction-associated steatohepatitis, or MASH, often overlap. Survodutide is being investigated in both settings. It activates GLP-1 and glucagon receptors, combining appetite-related effects with changes in metabolic signalling rather than targeting liver inflammation directly through a single pathway.
What the liver studies ask
MASH involves inflammatory injury alongside fat accumulation. Studies may assess improvement in MASH without worsening fibrosis, the liver’s scarring response. That endpoint is useful, but it does not mean fibrosis itself improved, and it does not yet measure fewer episodes of liver failure.
Why the detail changes the interpretation
A liver biopsy, an imaging measurement of liver fat and a change in body weight provide different information. How those changes relate is part of the research question. A percentage needs to identify what was measured: the proportion of participants meeting a tissue endpoint, for example, differs from their average weight change.
A longer view of benefit
Gastrointestinal symptoms and treatment discontinuation need to be weighed against the response. Existing liver damage also affects suitability and expected benefit. The programme tests relevant clinical questions in people, but a metabolic mechanism alone cannot establish who will avoid future liver complications.
Safety & status
Gastrointestinal symptoms, discontinuation and existing liver damage affect the benefit–risk assessment. Longer-term clinical liver outcomes remain important.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Does improvement in MASH mean less scarring?
Not necessarily. An endpoint requiring no worsening of fibrosis does not require fibrosis to improve.
Can a weight-loss percentage describe the liver result?
No. Mean weight change and the proportion meeting a liver endpoint are different measurements.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Survodutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Survodutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.